Trough level recommended (immediately before the next dose is due).
£29.50 per test
Lower limit of measuring range = 0.8 mg/L
Upper limit of measuring range = 45 mg/L
This Infliximab drug level assay is aligned to the 1st international infliximab standard NIBSC 16/170.
Managing inflammatory bowel disease patients with anti-TNF biological medicines such as Infliximab is challenging. Patients may respond well to treatment initially, only to encounter loss or response further ahead in their treatment pathway. Others may not respond to treatment at all. One approach to potentially improve outcomes for patients on Infliximab is to measure trough drug levels and to determine if patients have developed antibodies to the drug. However, drug level and antibody testing will only be useful if it actually creates positive outcomes for patients. The challenge lies in optimising when these analyses take place and how best to interpret the data in making clinical decisions that benefit patients.
If you have any further enquiries please contact the duty biochemist by email: firstname.lastname@example.org. Further help with interpretation of infliximab drug and anti-drug antibody results can be found here: Anti TNF monitoring guidance
We have demonstrated that the infliximab drug level assay measures the biosimilar drugs in the same manner as the parent drug. We offer a companion diagnostics service with free of charge infliximab drug and antibody testing for the following infliximab biosimilar agents:
(Please note; it is important to contact the relevant pharmaceutical company to ensure you meet the relevant terms and conditions of this service.)
10 working days
Can be added on to an existing request, stable in whole blood and serum for 7 days at room temperature (2).
We welcome referrals for Anti TNF monitoring. If you are a new requestor please complete the following form: New requestor form
We now also have the option to use NPEx for referral requesting.
Further information about sample requirements for this test can be found here: Infliximab and Anti-Infliximab Antibodies – further information